Business Standard

Is Mankind Pharma IPO worth a subscription? Here's what brokerages suggest

In the grey markets, shares of Mankind Pharma enjoyed a premium of Rs 90, which translated to a likely listing price of Rs 1,170 per share on the upper price band

Mankind Pharma
Web Exclusive Premium

Lovisha Darad New Delhi

Listen to This Article

The Rs 4,326-crore initial public offering (IPO) of Mankind Pharma will open for subscription from Tuesday, April 25. The price band is set in the range of Rs 1,026-1,080 per share. The offer-for-sale (OFS) portion consists of 40.1 million shares. 

Mankind Pharma is India's fourth largest pharma company in terms of domestic sales and third largest in terms of sales volume on a moving annual turnover (MAT) basis, as of December 2022. The company develops, manufactures, and markets a diverse range of acute-to-chronic therapies. Some of the well-known consumer healthcare products include Manforce, Prega News, Unwanted 72, Gas-o-Fast, Health OK,

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Apr 24 2023 | 12:34 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com